LONDON, June 22, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/631/Pre-Filled-Syringes-World-Market-Outlook-2011-2021

A new report by London-based business information company visiongain, predicts that world pre-filled syringe technology revenues will reach $3.9bn in 2015. That devices market generated $2.7bn (for the technology itself) in 2010, according to Pre-Filled Syringes: World Market Outlook 2011-2021, published in June 2011.

Pre-filled drug syringes are injecting devices that remove the filling step from another container before administering the injection. That drug delivery format is increasing in commercial importance with the expanding use of biological drugs and vaccines worldwide.

Expansion of the pre-filled syringe market will be dependent upon developments in syringe technologies and materials. Improvements to performance, product stability, convenience of use and cost-effectiveness will stimulate increasing use of pre-filled syringes and related devices this decade. Increased volume and viscosity handling capabilities and launches of devices that are easier to use are already benefiting sales of the devices and filled products.

Dr Gordon Low, healthcare reports editor, said: "The advantages are great, with pre-filled syringes taking over from traditional formats. Pre-fillable syringes constitute one of the fastest growing markets in the drug delivery and pharmaceutical packaging industries."

Visiongain forecasts that the pre-filled syringe technology and applications markets will expand steadily to 2021. The future of the pre-filled drug industry and market appears promising, with increasing demand in many therapeutic areas. This new study complements visiongain's wide range of analytical reports in healthcare and other industry areas.  

For sample pages and further information about the Pre-Filled Syringes: World Market Outlook 2011-2021 report please contact Sara Peerun on

Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207-3366100
http://www.visiongain.com

Table of Contents
1. Executive Summary
1.1 Pre-Filled Syringes Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Pre-Filled Syringes
2.1 The Pre-Filled Syringe Market
2.1.1 Market Overview
2.1.2 An Increasingly Alluring Sector
2.1.3 Greater Prevalence of Pre-Filled Syringes
2.1.4 Pre-Filled Syringes: The Current Situation
2.2 Introduction to Syringe Technology
2.2.1 A Brief Historical Perspective
2.3 The Design and Construction of Pre-Filled Syringes
2.3.1 Pre-Filled Syringe Components
2.3.2 Silicone and Biotechnology Products
2.3.3 Material Choice: Glass or Plastic?
2.3.4 Syringe Operation: Manual vs. Mechanical
2.3.5 Pharmaceutical Development: Extractables, Leachables and Manufacturing Residuals
2.3.6 Pharmaceutical Development: Functional Testing of Delivery Systems
2.4 Pre-Filled Syringes Offer Convenience over Alternatives
2.4.1 Pre-Filled Syringes for Lyophilized Drugs
2.5 Needle Stick Injuries and the Drive Towards Pre-Filled Syringes
2.5.1 Blood-Borne Pathogens and Needle Stick Injury
2.5.2 Accidental Needle Stick Injuries: a Serious Healthcare Problem
2.6 Injection Delivery Devices
2.6.1 Pen Injectors
2.6.2 Insulin Pens
2.6.3 Auto-Injectors
2.6.4 Needle-Free Injectors
2.6.5 Selection of Injection Devices

3. The World Pre-Filled Syringes Technology Market, 2011-2021
3.1 The World Pre-Filled Syringes Market in 2010
3.2 Growing Market for Pre-Filled Syringes
3.2.1 Sales Forecast for Pre-Filled Syringe Units, 2010-2015
3.2.2 Sales Forecast for Pre-Filled Syringe Units, 2016-2021
3.2.3 Sales Forecast for Pen Systems and Autoinjectors Market, 2010-2015
3.2.4 Sales Forecast for Pen Systems and Autoinjectors Market, 2016-2021
3.2.5 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2010-2015
3.2.6 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2016-2021
3.2.7 Sales Forecast for Total Pre-Filled Syringes Market, 2010-2015
3.2.8 Sales Forecast for Total Pre-Filled Syringes Market, 2016-2021
3.2.9 Summary: Overall World Pre-Filled Syringes Market, 2010-2021
3.3 Leading National Markets for Pre-Filled Syringes, 2010-2021
3.3.1 The US Pre-Filled Syringe Market, 2010-2021
3.3.2 The Japanese Pre-Filled Syringe Market, 2010-2021
3.3.3 The Leading European Pre-Filled Syringe Markets, 2010-2021
3.3.4 Emerging-Economy Pre-Filled Syringe Markets
3.3.5 The Chinese Pre-Filled Syringe Market, 2010-2021
3.3.6 The Indian Pre-Filled Syringe Market, 2010-2021
3.4 Summary of National Market Forecasts

4. Worldwide Market for Pre-Filled Syringes and Related Technology
4.1 Therapeutic Areas Offering Growth Opportunities
4.2 Development of Biologics and Vaccines Will Drive the Pre-Filled Syringes Market from 2011-2021
4.3 The Leading Sectors of Biological Drugs Market, 2010
4.3.1 Monoclonal Antibodies Currently Lead the Biologics Market
4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and Implications for the Pre-Filled Syringes Market
4.3.2 The Human Insulins Class Will Exhibit Strong Growth
4.3.3 Erythropoietin Products - How Will Reported Safety Affect Sales?
4.3.3.1 Erythropoietin Products Forecast, 2011-2021
4.3.4 The Interferons Class will Show an Increase in Revenues from 2011-2015
4.3.4.1 Long-Term Forecast for the Interferons Class
4.3.5 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2011-2021
4.3.6 Recombinant Coagulation Factors Will Show Steady Growth
4.3.7 Other Therapeutic Proteins
4.3.8 The Biosimilars Market, 2010
4.3.8.1 Forecast for the World Biosimilars Market, 2011-2021
4.3.9 Forecast for the Vaccines Market, 2011-2021
4.4 The Pre-Filled Syringe Drug Market: Conclusions

5. Leading Pre-Filled Syringe Products on the Market
5.1 Introduction
5.2 Insulins and Antidiabetic Agents
5.2.1 Leading Human Insulins and Analogues
5.2.1.1 Lantus
5.2.1.2 Humalog
5.2.1.3 Novorapid
5.2.1.4 NovoMix/NovoLog
5.2.1.5 Levemir
5.2.1.6 Actraphane HM
5.3 Byetta/Exenatide LAR: Non-Insulin Revolutionary Injectable
5.3.1 Byetta's Strengths
5.3.2 Restraints on Byetta
5.4 Leading Biotech Products in Pre-Filled Syringe Format
5.4.1 Humira
5.4.1.1 Humira - Leading Biotech Drug
5.4.1.2 Humira Market Forecast, 2011-2015
5.4.1.3 Long-Term Prospects for Humira
5.4.2 Enbrel
5.4.2.1 Amgen Continues to Benefit from Enbrel Sales
5.4.2.2 Enbrel Sales Will Show an Initial Increase
5.4.2.3 Study Eases Fears of TNF Blocker Cancer Risk
5.4.2.4 New Enbrel Delivery System
5.4.2.5 Enbrel Lifecycle Management
5.4.2.6 Sales of Enbrel Will Eventually Decline
5.4.2.7 Enbrel Faces Competition from Several Other Biotech Drugs
5.4.2.8 Competition from Biosimilars?
5.4.3 Neulasta
5.4.3.1 Neulasta Sales Forecast, 2011-2021
5.5 Other Pre-Filled Drugs on the Market
5.5.1 Avonex
5.5.1.1 Avonex Market Forecast, 2011-2021
5.5.1.2 Avonex Faces Competition from New Oral MS Drugs
5.5.2 Rebif
5.5.2.1 Rebiject II
5.5.2.2 RebiSmart
5.5.2.3 Rebif Sales Forecast, 2011-2015
5.5.2.4 Rebif Sales Forecast, 2016-2021

6. Leading Companies in the Pre-Filled Syringe Field
6.1 Introduction
6.2 Becton, Dickinson and Company (BD)
6.2.1 Overview
6.2.2 Global Presence
6.2.3 Distribution
6.2.4 Focus on Parenteral and Biomaterial Technologies
6.2.5 Products
6.2.5.1 BD Hypak SCF Syringe Systems
6.2.5.2 BD Sterifill SCF Syringe Systems
6.2.5.3 Self-Injection Systems
6.2.5.3.1 BD Physioject Disposable AutoInjector
6.2.5.3.2 BD MicroInfusor Automatic Injection System
6.2.5.3.3 BD Liquid Dry Injector Disposable Pen Injector
6.2.5.3.4 BD Pens
6.2.5.4 Detachable and Integrated Safety Systems
6.2.5.5 BD Soluvia Pre-Fillable Microinjection System
6.2.5.6 BD Uniject SCF: Auto-Disable Injection System
6.2.6 R&D
6.2.7 Revenues
6.3 Vetter Pharma-Fertigung
6.3.1 Overview
6.3.2 Global Presence
6.3.3 Business Interests
6.3.3.1 Vetter Development Service
6.3.3.2 Vetter Commercial Manufacturing
6.3.3.3 Vetter Solutions
6.3.4 Capabilities
6.3.5 R&D
6.3.6 Product Focus
6.3.6.1Dual-Chamber Technology
6.3.6.2 Single-Chamber Syringes and Cartridges
6.3.7 Future Outlook
6.4 SCHOTT
6.4.1 Overview
6.4.2 Global Presence
6.4.3 SCHOTT's Pharmaceutical Systems
6.4.4 SCHOTT's Pharmaceutical Packaging Business Segment
6.4.5 Products: Pre-Fillable Polymer Syringes
6.4.5.1 SCHOTT TopPac Pre-Fillable Syringes
6.4.5.2 SCHOTT InJentle: Innovative Staked Needle Syringe
6.4.6 Revenues
6.5 Abbott Laboratories
6.5.1 Overview
6.5.2 Market Areas and Products
6.5.3 Pre-Filled Syringe Products: Humira
6.5.4 Abbott's Other Syringe Products
6.5.4.1 Abbott Abboject
6.5.4.2 Abbott LifeShield
6.5.4.3 Abbott Ansyr
6.5.4.4 Abbott Carpuject Injector
6.5.5 Revenues and Growth
6.6 Ypsomed
6.6.1 Overview
6.6.2 Global Presence
6.6.3 Products
6.6.3.1 Insulin Pen Injectors
6.6.3.2 Pen Injectors for Other Indications
6.6.3.3 Monodose Pens for Dual-Chamber Cartridges
6.6.3.4 Disposable Auto-Injectors
6.6.3.5 Standard Pen Needles Penfine and Clickfine
6.6.3.6 Safety Pen Needle Clickfine AutoProtect
6.6.4 R&D
6.6.5 Revenues and Growth
6.6.6 Future Outlook
6.7 Gerresheimer
6.7.1 Overview
6.7.2 Business Operations
6.7.3 Locations
6.7.4 Gerresheiemer's Tubular Glass Division
6.7.5 Syringe Systems
6.7.5.1 Technology Centre for Syringe Systems
6.7.5.2 Technical Competence Centre for Plastic Products
6.7.6 Revenues
6.7.7 R&D
6.7.8 Outlook
6.8 MGlas (MG)
6.8.1 Overview
6.8.2 Products
6.8.2.1 Pre-Fillable Syringes/Cartridges/Vials
6.8.2.2 MG Innovative Needles

7. Analysis of Forces Influencing the Pre-Filled Syringes Industry and Market
7.1 Introduction
7.2 Commercial Drivers of the Pre-Filled Syringes Market
7.2.1 Cost Savings - a Powerful Motivator?
7.2.2 Glass Pre-Fillable Syringes
7.2.3 Plastic Pre-Fillable Syringes
7.2.4 Convenience and Safety Issues
7.2.5 Cost Efficiencies
7.2.6 Product Differentiation and Customization
7.2.7 Reimbursement
7.3 Commercial Restraints for the Pre-Filled Syringes Market
7.3.1 Pre-Filled Syringe Systems Have Limitations
7.3.2 Patients Prefer Pills
7.4 Emerging Trends and Opportunities in the Pre-Filled Syringes Market: Opportunity Analysis
7.5 Challenges Facing the Pre-Filled Syringes Market
7.5.1 Needle Stick Safety and Prevention Laws
7.5.1.1 Compliance with Needle Stick Safety and Prevention Laws
7.5.1.2 Main Findings Leading to the Legislation
7.5.1.3 Increasing Exposure to Blood-Borne Pathogens
7.5.1.4 OSHA 1991 Regulation Standard
7.5.1.5 Estimated Needle Stick and Other Percutaneous Injuries Occurring Annually in the US
7.5.1.6 Newer Engineering Controls and Safer Medical Devices
7.5.1.7 CDC Estimates 80% of Sharps Injuries Are Preventable
7.5.1.8 OSHA 200 Log Surveillance System
7.5.1.9 Training and Education
7.5.1.10 Summary of Regulatory and Legislative Requirements
7.5.2 State-Level OSHA Plans and Federal Legislation
7.5.3 BPS Enforcement by OSHA
7.5.4 Laws in Other International Markets
7.5.5 EU on the Threshold of New Laws to Tackle Needle Stick Injuries
7.5.6 High Entry Barriers, Few Suppliers
7.5.7 Product Stability a Major Concern
7.5.7.1 Leachables and Safety
7.5.7.2 Compatibility between Drug Product and Pre-Filled Syringes
7.5.7.3 Eprex and Leaching
7.5.7.4 Protein Aggregation Related to Leached Tungsten
7.5.7.5 Protein Aggregation Related to Silicone Oil
7.5.8 Product Stability and Quality Assurance Programme
7.5.8.1 A Paediatric H1N1 Vaccine Withdrawn from the Market
7.5.8.2 Voluntary Withdrawal of Five Lots of Flu Vaccine
7.5.8.3 Shelf Life of Some H1N1 Vaccine Batches Apparently Changed
7.5.8.4 Contamination Problems with Leachables in Pre-Fillable Syringes
7.5.8.5 West and Daikyo Offer Syringe Systems to Minimise Leaching
7.5.8.6 SCHOTT AG Launched InJentle Syringe to Improve Drug Stability
7.6 Conclusions

8. Opinions from Our Survey
8.1 Interview 1: Dr Phil Lever, Commercial Director, Cambridge Consultants, Cambridge, UK
8.1.1 Current Market Worth for Pre-Filled Syringes
8.1.2 Key Unmet Needs
8.1.3 Research and Development
8.1.4 Problems with the Current Use of Pre-Filled Syringes
8.1.5 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.1.6 Drawbacks of Pre-Filled Syringes
8.1.7 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
8.1.8 Complexities for Making New Pre-Filled Syringes
8.1.9 Preferred Component Materials, Surface Treatments and Filling Processes
8.1.10 Technologies, Developments and R&D
8.1.11 Main Therapeutic Areas Offering Growth Opportunities
8.1.12 The Future of PFS over the Next 10-15 Years
8.1.13 Main Threats Facing the PFS Industry
8.1.14 Novel Technology/Developments
8.1.15 Potential Replacement
8.2 Interview 2: Authority from a Company in the Sector (Views Provided Anonymously)
8.2.1 Unmet Needs and Market for Pre-Filled Syringes
8.2.2 Competing Products and Alternatives to Pre-Filled Syringes
8.2.3 Disadvantages and Drawbacks with Pre-Filled Syringes and Related Devices
8.2.4 Pre-Filled Syringe Products, Safety and Vaccines
8.2.5 Challenges for Complex Biological Therapeutics in Pre-Filled Syringes
8.2.6 Versatility of Pre-Filled Syringes
8.2.7 Dual-Chamber Pre-Filled Syringe Systems
8.2.8 Syringe Material: Glass vs. Plastic
8.2.9 Future Developments in Pre-Filled Syringe Systems
8.2.10 Progress in Needle Stick Injury (NSI) Legislation for Europe
8.2.11 NSI Legislation and Implications for Stakeholders
8.3 Interview 3: Dr Marja van der Heijden, Pharmaceutical Formulations Scientist, Abbott Healthcare Products B.V., Amsterdam, Netherlands
8.3.1 The Main Unmet Needs
8.3.2 Research and Development
8.3.3 Research Challenges Facing Pre-Filled Syringe Technology
8.3.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
8.3.5 Drawbacks of Pre-Filled Syringes
8.3.6 Technologies, Developments and R&D

9. Conclusions from Our Research and Analyses
9.1 Introduction
9.2 Leading Players in the Market
9.3 Commercial Drivers of the Pre-Filled Syringe Market
9.4 Future Outlook
9.4.1 Further Advances?
9.4.2 Future Developments in Pre-Filled Syringe Systems
9.5 Concluding Remarks

List of Tables
Table 2.1 Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2011
Table 2.2 Historical Timeline for Development of Syringe Technology
Table 2.3 Components for Pre-Fillable Syringes
Table 2.4 Leading Brands of Insulin in Pen Syringe Format, 2010
Table 2.5 Main Factors Increasing the Interest in Auto-Injectors, 2011
Table 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015
Table 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021
Table 3.3 Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015
Table 3.4 Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021
Table 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2010-2015
Table 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2016-2021
Table 3.7 Total Pre-Filled Syringes: World Sales Forecast, 2010-2015
Table 3.8 Total Pre-Filled Syringes: World Sales Forecast, 2016-2021
Table 3.9 Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2010-2015
Table 3.10 Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2016-2021
Table 3.11 Leading Pre-Filled Syringe National Market Forecasts, 2010-2021
Table 4.1 Leading Product Classes Driving the Pre-Filled Syringes Market, 2010
Table 4.2 List of Some Currently Marketed Monoclonal Antibodies, 2011
Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2010-2015
Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2016-2021
Table 4.5 Insulins Market: World Sales Forecast, 2010-2015
Table 4.6 Insulins Market: World Sales Forecast, 2016-2021
Table 4.7 Erythropoietins Market: World Sales Forecast, 2010-2015
Table 4.8 Erythropoietins Market: World Sales Forecast, 2016-2021
Table 4.9 List of Some Currently Marketed Interferon Drugs, 2011
Table 4.10 Interferons Market: World Sales Forecast, 2010-2015
Table 4.11 Interferons Market: World Sales Forecast, 2016-2021
Table 4.12 G-CSF Market: World Sales Forecast, 2010-2015
Table 4.13 G-CSF Market: World Sales Forecast, 2016-2021
Table 4.14 List of Some Currently Marketed Recombinant Coagulation Factors, 2011
Table 4.15 Recombinant Coagulations Factors Market: World Sales Forecast, 2010-2015
Table 4.16 Recombinant Coagulations Factors Market: World Sales Forecast, 2016-2021
Table 4.17 List of Some Marketed Human Growth Hormones, 2011
Table 4.18 List of Some Currently Marketed Pre-Filled Immunosuppressants Products, 2011
Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2010-2015
Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2016-2021
Table 4.21 List of Some Currently Marketed Biosimilar Drugs, 2011
Table 4.22 Biosimilars Market: World Sales Forecast, 2010-2015
Table 4.23 Biosimilars Market: World Sales Forecast, 2016-2021
Table 4.24 List of Some Currently Marketed Vaccines, 2011
Table 4.25 Total Vaccines Market: World Sales Forecast, 2010-2015
Table 4.26 Total Vaccines Market: World Sales Forecast, 2016-2021
Table 5.1 Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2011
Table 5.2 Lantus: World Sales Forecast, 2010-2015
Table 5.3 Lantus: World Sales Forecast, 2016-2021
Table 5.4 Humalog: World Sales Forecast, 2010-2015
Table 5.5 Humalog: World Sales Forecast, 2016-2021
Table 5.6 Novorapid: World Sales Forecast, 2010-2015
Table 5.7 Novorapid: World Sales Forecast, 2016-2021
Table 5.8 NovoMix/NovoLog: World Sales Forecast, 2010-2015
Table 5.9 NovoMix/NovoLog: World Sales Forecast, 2016-2021
Table 5.10 Levemir: World Sales Forecast, 2010-2015
Table 5.11 Levemir: World Sales Forecast, 2016-2021
Table 5.12 Actraphane HM: World Sales Forecast, 2010-2015
Table 5.13 Actraphane HM: World Sales Forecast, 2016-2021
Table 5.14 Byetta: World Sales Forecast, 2010-2015
Table 5.15 Byetta: World Sales Forecast, 2016-2021
Table 5.16 Humira: World Sales Forecast, 2010-2015
Table 5.17 Humira: World Sales Forecast, 2016-2021
Table 5.18 Enbrel: World Sales Forecast, 2010-2015
Table 5.19 Enbrel: World Sales Forecast, 2016-2021
Table 5.20 Neulasta: World Sales Forecast, 2010-2015
Table 5.21 Neulasta: World Sales Forecast, 2016-2021
Table 5.22 Avonex: World Sales Forecast, 2010-2015
Table 5.23 Avonex: World Sales Forecast, 2016-2021
Table 5.24 Rebif: World Sales Forecast, 2010-2015
Table 5.25 Rebif: World Sales Forecast, 2016-2021
Table 5.26 Some Leading Pre-Filled Syringe Vaccine Products on Market, 2011
Table 6.1 Leading Companies in Pre-Filled Syringes Market, 2011
Table 7.1 SWOT Analysis of World Pre-Filled Syringes Market: Strengths, 2010-2021
Table 7.2 SWOT Analysis of World Pre-Filled Syringes Market: Weaknesses, 2010-2021
Table 7.3 SWOT Analysis of World Pre-Filled Syringes Market: Opportunities and Threats, 2010-2021
Table 7.4 Risk of Infection Following Needle Stick Incident, 2011
Table 7.5 Examples of Leachables Impacting on Safety and Product Quality
Table 9.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010, 2012, 2015, 2017, 2019 and 2021
Table 9.2 Pre-Filled Syringes: World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 and 2021

List of Figures
Figure 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015
Figure 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021
Figure 3.3 Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015
Figure 3.4 Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021
Figure 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2010-2015
Figure 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2016-2021
Figure 3.7 Total Pre-Filled Syringes Market: World Sales Forecast, 2010-2015
Figure 3.8 Total Pre-Filled Syringes Market: World Sales Forecast, 2016-2021
Figure 3.9 US and Other Leading Pre-Filled Syringe Market Forecasts, 2010-2021
Figure 3.10 Leading National Pre-Filled Syringe Market Forecasts (Lower Range), 2010-2021
Figure 3.11 Pre-Filled Syringe Sales in Leading National Markets, 2010
Figure 3.12 Pre-Filled Syringe Sales in Leading National Markets, 2015
Figure 3.13 Pre-Filled Syringe Sales in Leading National Markets, 2018
Figure 3.14 Pre-Filled Syringe Sales in Leading National Markets, 2021
Figure 4.1 Monoclonal Antibodies Market: World Sales Forecast, 2010-2021
Figure 4.2 Insulins Market: World Sales Forecast, 2010-2021
Figure 4.3 Erythropoietins Market: World Sales Forecast, 2010-2021
Figure 4.4 Interferons Market: World Sales Forecast, 2010-2021
Figure 4.5 G-CSF Market: World Sales Forecast, 2010-2021
Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2010-2021
Figure 4.7 Other Therapeutic Proteins Market: World Sales Forecast, 2010-2021
Figure 4.8 Biosimilars Market: World Sales Forecast, 2010-2021
Figure 4.9 Vaccines Market: World Sales Forecast, 2010-2021
Figure 5.1 Lantus: World Sales Forecast, 2010-2021
Figure 5.2 Humalog: World Sales Forecast, 2010-2021
Figure 5.3 Novorapid: World Sales Forecast, 2010-2021
Figure 5.4 NovoMix/NovoLog: World Sales Forecast, 2010-2021
Figure 5.5 Levemir: World Sales Forecast, 2010-2021
Figure 5.6 Actraphane HM: World Sales Forecast, 2010-2021
Figure 5.7 Byetta: World Sales Forecast, 2010-2021
Figure 5.8 Humira: World Sales Forecast, 2010-2021
Figure 5.9 Enbrel: World Sales Forecast, 2010-2021
Figure 5.10 Neulasta: World Sales Forecast, 2010-2021
Figure 5.11 Avonex: World Sales Forecast, 2010-2021
Figure 5.12 Rebif: World Sales Forecast, 2010-2021
Figure 6.1 BD Medical Sales Revenues: Fiscal Year, 2010
Figure 6.2 SCHOTT Sales Revenues by Region, 2009-2010
Figure 6.3 Abbott's Net Sales Worldwide, 2007-2010
Figure 6.4 Distribution of Gerresheimer Workforce, 2010-2011
Figure 6.5 Gerresheimer Sales by Division, 2010
Figure 6.6 Gerresheimer Sales by Region, 2010
Figure 7.1 Preference for Pre-Filled Syringes by Healthcare Professionals, 1995-1999
Figure 7.2 Pattern of Sharps Injury to Healthcare Workers, 1995-1999
Figure 9.1 Pre-Filled Syringes: World Revenue and Unit Sales Forecast, 2010-2021

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0)207-336-6100

SOURCE Visiongain